Ergoteles’s CureVac CVAC Stock Holding History

Ergoteles’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-98,100	Closed	-$1.33M	–	1626
2022 Q2	$1.33M	Buy	+98,100	New	+$1.62M	0.04%	428
2021 Q4	–	Sell	-43,358	Closed	-$2.37M	–	1300
2021 Q3	$2.37M	Buy	+43,358	New	+$2.61M	0.09%	237

Other funds holding CVAC

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's CVAC Position: Q3 2022 in Review

Ergoteles sold out of CureVac (CVAC) in Q3 2022, closing a stake of 98,100 shares — an estimated $1.33M sold.

Ergoteles first reported a position in CVAC in Q3 2021 and held it in 2 quarters. The position peaked at $2.37M in Q3 2021. 83 funds tracked by Wall St. Rank hold CVAC as of Q3 2022.

Ergoteles reported no remaining CureVac position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 98,100 CureVac shares in Q3 2022, an estimated $1.33M.
Ergoteles first reported a position in CureVac in Q3 2021 and held it in 2 quarters.
Ergoteles's CureVac position peaked at $2.37M in Q3 2021.
83 funds tracked by Wall St. Rank held CureVac as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.